President’s Message

I hope everyone is having a wonderful summer and enjoying fun in the sun. I wanted to let the membership know that longtime NASCSA member and our present IT guru, Bill Ward has been a little under the weather. On behalf of the Executive Committee, we wish Bill our thoughts and prayers for a fast recovery.

Lastly, the purpose of the NASCSA is to provide a forum for the discussion and exchange of information and ideas, to develop, implement and monitor ongoing strategies and to curtail the abuse, misuse and diversion of controlled substances. Further, in part, to limit the inappropriate use and diversion of controlled substances and to provide a unified voice of its membership in the appropriate use of controlled substances. This year we can strive to meet this purpose by planning to attend the NASCSA annual conference scheduled October 17-20, 2017 in San Antonio, Texas. Please plan on joining us to exchange ideas, information, and views on legal and regulatory issues relating to controlled substances. Hope to see you there.

David Dryden, President, NASCSA

Save the Date for Our Annual Conference

The 33rd annual conference will take place at the Drury Plaza Hotel Riverwalk October 17-20, 2017 in San Antonio, Texas. Registration information as well as information on hotel accommodations is available on our website here. We would strongly urge all attendees to book your hotel early as this is a particularly busy time of year. Check the website on a regular basis for updates. A preliminary program has been posted including a number of exciting topics including presentations by the Drug Enforcement Administration, Prescription Monitoring Programs, an update from various federal agencies, drug trends, issues for drug take-backs, a pharmacist’s story on his road to recovery, drug abuse trends among veterans. As always, this year’s program promises to be exciting and interactive. In addition, we are pleased to
NASCSA Monitoring Prescription Monitoring Program Legislation Filed in Congress

NASCSA is closely monitoring two bills filed in both the House and Senate "The Prescription Drug Monitoring Act of 2017 - H.R. 1854 and S778 that may be of interest to our members. We will keep you posted as we learn more.

NASCSA Welcomes Our Newest Sponsors

NASCSA would like to welcome its newest sponsors: Greenwich Bioscience (Platinum Sponsor); QuintileIMS (Gold Sponsor); McKesson Corporation (Silver Sponsor) and Teva Pharmaceuticals (Silver Sponsor). For more information about sponsorship opportunities and how to become a sponsor please click here.

Alaska Seeking Pharmacy Program Manager

The State of Alaska is seeking a Pharmacy Program Manager to coordinate the Board of Pharmacy and the Prescription Drug Monitoring Programs. Pharmacy degree not required. Visit here found.

From the States...

Idaho - Issued a final rule of the Board of Pharmacy amends regulations under IDAPA 27.01.01.114 to revise requirements for Schedule II controlled substances to comply with federal law. The rule allows patients to receive fewer Schedule II controlled substance pills than written by a prescriber while not forfeiting the balance if picked up within a certain time frame. The rule is effective March 29, 2017. Contact: Alex Adams; Board of Pharmacy; 208-334-2356; alex.adams@bop.idaho.gov

Maine - Proposed rule of the Department of Professional and Financial Regulation, Board of Licensure in Medicine, State Board of Nursing, Board of Osteopathic Licensure, and Board of Licensure of Podiatric Medicine, repeals and readopts regulations under MAC Chapter 21 regarding the use of controlled substances for the treatment of pain. The joint rule specifies requirements for clinicians subscribing controlled substances for control pain, including that clinicians conduct a risk assessment on patients, obtain informed consent, and conduct proper documentation. The rule also requires clinicians to consider the use of nonpharmacologic methods and noncontrolled drugs in treatment of pain prior to prescribing controlled substances. In addition, the rule requires clinicians to maintain current clinical knowledge by complying with continuing education requirements. Comments are due June 2, 2017. Contact: Dennis Smith; Board of Licensure in Medicine; 207-287-3605; Dennis.Smith@Maine.gov

Massachusetts - Notice of the Department of Public Health, Board of Registration in Pharmacy, announces the issuance of circular letter (BHPL-DCP 17-5-101) to update the Prescription Drug Monitoring Program Data Submission Dispenser Guide (Version 3.0). The update requires state pharmacies to report gabapentin, a Schedule VI medication, via the program clearinghouse. The notice specifies that as of Aug. 1, 2017, pharmacies must report all required data for dispensed prescriptions of gabapentin except the customer ID, which will be required beginning Aug. 1, 2018. The notice also specifies that reporting is to comply with the American Society for Automation in Pharmacy 4.2 standards. In addition, the notice provides additional reporting requirements for all substances in Schedule II through V. Contact: DPH, Prescription Drug Monitoring Program; 617-753-7310; mapmp.dph@state.ma.us

Texas - Issued a final rule of the Board of Pharmacy amends regulations under 15 WVCSR 8 regarding the Controlled Substances Monitoring Program. The rule requires opioid antagonist dispensing to be reported to the program. The rule also specifies that the date to be reported into the system for
NASCSA News - June 2017 Newsletter

www.workplace.alaska.gov for details. Recruitment closes June 15, 2017, at 5 p.m. The State of Alaska complies with Title I of the ADA and is an equal opportunity employer.

**Interested in PMP Legislation?**

Due to our ongoing collaboration with the National Alliance for Model State Drug Laws (NAMSDL), we have been provided with an updated compilation of information on state and federal legislation and regulations pertaining to Prescription Monitoring Programs as a courtesy to members. The latest listing is found [here](#) under the PMP section of our website.

**SAMHSA Study Finds PDMPs Associated With Significant Decline in "Doctor Shopping" and Non-Medical Use of Prescription Drugs**

Prescription drug monitoring programs (PDMPs) are effective in preventing patients from seeking multiple prescribers to prescribe them opioids, according to a recent study by Substance Abuse and Mental Health Services Administration (SAMHSA). The study, Prescription Drug Monitoring Programs, Nonmedical Use of Prescription Drugs, and Heroin Use: Evidence from the National Survey of Drug Use and Health, also found that PDMPs reduced the "date filled" is the date the controlled substance dispensed is actually delivered to the patient or the patient's agent. In addition, the rule clarifies provisions concerning filing "zero reports" when there is no controlled substance dispensing from a reporter and accounts for the reporting of corrections to the system within seven days of finding any error by a reporter. The rule is effective April 28, 2017. Contact: Board of Pharmacy; 304-558-0558

**Texas** - The Texas legislature passed House Bill 2651 which amends the Texas Controlled Substances act, Section 481.0766. Effective September 1, 2017 wholesale drug distributors shall report to the Texas State Board of Pharmacy the information that the distributor is required to report to the Automation of Reports and Consolidated Orders System (ARCOS) of the Federal Drug Enforcement Administration for the distribution of a controlled substance by the distributor to a person in the state.

NASCSA members and other interested parties may not be aware of an important (and complimentary) resource of great value on regulatory changes occurring in other states related to controlled substances, prescription monitoring programs, scheduling changes, recordkeeping/security requirements and licensure changes to name a few. "State Regulatory Updates" is compiled each month and is posted on NASCSA's website located [here](#). We would strongly encourage you to check this section of our website as it may provide insights of what other state agencies are doing nationally and serve as a vital resource and information sharing.

**NASCSA Committees Hard at Work**

This year NASCSA has six committees that have been hard at work on a variety of projects. Committee members, comprised of volunteers from member states as well as associate members which are the backbone of the organization and we would encourage all members to consider volunteering. For a list of committee members click [here](#). Below is a description of committee highlights.

**Grants, Sponsorships and Membership** - In addition to developing the criteria for this year's travel scholarship, members of the committee will be reviewing the applicants to make recommendations to the Executive Committee after the receipt of all applicants. The Committee is also in the process of updating its newsletter policy and will be working on updating NASCSA's brochure to reflect bylaw changes passed at the annual conference. The committee is also brainstorming about prospective sponsors and identifying other individuals and organizations to reach out in order to expand its membership and sponsorship base to continually ensure that NASCSA continues to be self-sustaining in the future. If you are aware of potential organizations that we might want to reach out to please contact us! Speaking of sponsors, we would like to thank those [sponsors](#) who continue to support NASCSA and the important work we do.

**Program** - Members of the committee are hard at work working finalizing the 2017 conference. As noted above, a
The non-medical use of prescription drugs by an average of 10 days a year per user. In locations where PDMP participation was mandatory, the reduction in non-medical use was even greater, notes a SAMHSA.

To date, 41 states/jurisdictions have deployed NABP PMP InterConnect®, a highly secure communications exchange platform that facilitates the transmission of prescription monitoring program (PMP) data across state lines to authorized requestors, while ensuring that each state’s data-access rules are enforced. PMP InterConnect allows participating state PMPs across the United States to be linked, providing a more effective means of combating drug diversion and drug abuse nationwide. NABP continues to work with other states to facilitate their participation.

Additional information about PMP InterConnect is available in the Initiatives section of the NABP website.

**DEA Changes Registration Renewal Process**

As of January 2017, Drug Enforcement Administration (DEA) will no longer send its second renewal notification by mail. Instead, an electronic reminder to renew will be sent to the email address associated with the DEA registration.

In addition, DEA will retain its current policy and procedures with respect to renewal and reinstatement of registration. The policy is described below.

**Survey/Data** - The committee has just begun its work of developing potential surveys of the membership. In addition, we have been working with our webmaster Bill Ward on additional enhancements to our new database management software that has helped NASCSA to update contact information quickly as well as updates on various regulations/statutes. We would ask that state agencies check the state profile page here for their respective states to let us know whether any information needs updating. If there is information you feel would be helpful, please forward those suggestions.

**Resolutions/Bylaws** - The committee is in the process of preparing minor changes to the bylaws following last year’s annual business conference. The proposed changes to the bylaws will be distributed later this summer. In addition, the committee will be reviewing potential resolutions for consideration by members at the annual conference. All members are strongly encouraged to provide their suggestions on possible resolutions and ideally suggest language as soon as possible. All members are permitted to submit proposed resolutions in accordance with our Bylaws, found at Article XI. Draft resolutions will be distributed in early September (45 days prior to the annual meeting). Any proposed bylaw changes will be distributed 60 days in advance of the meeting.

**Prescription Monitoring Program** - The committee is meeting on a monthly basis and has a number of important tasks it will be working on this year including but not limited to the following: 1) developing a strategy to solicit support for the PMP Model Act from various organizations; 2) finalizing Prescription Monitoring Program topics/speakers for this year’s conference in October that are of most importance to PMP administrators; 3) performing a gap analysis; 4) discussing potential resolution(s) for consideration; and 5) discussing data and analytic metric sharing. More information will be provided on these important initiatives as they progress.

**Policy and Procedures** - A committee has been formed to review NASCSA’s written policies and procedures to ensure that these documents are current and up to date. These policies are to ensure the smooth operation of the organization and to provide a roadmap for overall operations of the organization.

**Dues Reminder**

Dues notices have been sent out to members and associate members. Dues are for 2017-2018 and run from July 1-June 30. If you have not received your notice please contact the office.

We hope you enjoyed this latest edition of NASCSA News.
If a renewal application is submitted in a timely manner prior to expiration, the registrant may continue operations, authorized by the registration, beyond the expiration date until final action is taken on the application.

DEA allows the reinstatement of an expired registration for one calendar month after the expiration date. If the registration is not renewed within that calendar month, an application for a new DEA registration will be required.

Regardless of whether a registration is reinstated within the calendar month after expiration, federal law prohibits the handling of controlled substances or List 1 chemicals for any period of time under an expired registration. Additional information is available here.

**DEA Scheduling Actions**

On June 2 The US Drug Enforcement Administration (DEA) issued a notice of intent to issue a temporary order to schedule the synthetic opioid, N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide (acrylfentanyl or acryloylfentanyl), into Schedule I pursuant to the temporary scheduling provisions of the Controlled Substances Act. This action is based on a finding by the Administrator that the placement of this synthetic opioid into Schedule I of the Controlled Substances Act is necessary to avoid an imminent hazard to the public safety. When it is issued, the temporary

We strongly encourage members and others to share information from their respective agencies for consideration for our newsletter. Please email KathyKeough@nascsa.org with your articles and ideas.

Sincerely,

*Kathy Keough*
Executive Director
scheduling order will impose the administrative, civil, and criminal sanctions and regulatory controls applicable to Schedule I controlled substances under the Controlled Substances Act on the manufacture, distribution, reverse distribution, possession, importation, exportation, research, and conduct of instructional activities, and chemical analysis of this synthetic opioid. The notice is found here.

On Twitter?

NASCSA is pleased to announce that it is now on Twitter. Make sure to follow us @NASCSA.